Breakthrough in EBV MHC-I Tetramer Technology: Decoding Nasopharyngeal Carcinoma Immune Response to Advance Precision Immunotherapy Development

Epstein-Barr virus (EBV, human herpesvirus 4), recognized as the first DNA virus conclusively linked to human oncogenesis, continues to garner extensive attention for its pathogenic mechanisms and clinical translation potential. Epidemiological data indicates that EBV contributes to approximately 200,000 new cases of virus-associated malignancies annually worldwide, with EBV-related deaths accounting for 1.8% of all cancer-related mortality.

Immunity/Inflamma
  • Recent Advances
  • Product Information
Recent Advances
EBV MHC Tetramer
Epstein-Barr virus (EBV), a human herpesvirus (type 4), is the first DNA virus confirmed to be associated with human tumor development, and its pathogenesis and clinical value are of sustained interest. Epidemiological data shows approximately 200,000 new cases of EBV-related malignant tumors worldwide each year, accounting for 1.8% of such deaths. EBV has broad tissue tropism and can induce various malignancies, including B-cell lymphomas (e.g., Burkitt lymphoma, classical Hodgkin lymphoma), NK/T-cell lymphomas (nasal type), epithelial carcinomas (nasopharyngeal carcinoma, gastric adenocarcinoma), and mesenchymal tumors (leiomyosarcoma). Notably, epithelial-cell-derived tumors account for over 80% of EBV-related malignancies, with nasopharyngeal carcinoma (NPC) having an EBV DNA detection rate exceeding 90%, making it a research hotspot for EBV-targeted immunotherapy.
  1. EBV Life Cycle and Latent Infection Characteristics
The EBV infection cycle includes acute and latent phases. Transmitted primarily via saliva, the virus initially infects oropharyngeal epithelial cells and B lymphocytes, establishing latency in B cells. Under immune suppression or microenvironmental changes, the latent virus can reactivate into the lytic cycle, expressing lytic proteins that induce host cell malignant transformation. This dynamic virus-host interaction is the molecular basis for EBV-related tumorigenesis.
  1. Key EBV Proteins for Immunotherapy
During latent infection, EBV expresses 11 characteristic viral proteins: six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP), three latent membrane proteins (LMP1, LMP2A, LMP2B), and two non-coding RNAs (EBER1, EBER2). Based on protein expression profiles, EBV latency is classified into three subtypes:
  • Latency I: Only EBNA1 and EBERs are expressed, seen in Burkitt lymphoma.
  • Latency II: EBNA1, LMP1/2, and EBERs are expressed, linked to NPC and Hodgkin lymphoma.
  • Latency III: Full-genome expression (all EBNAs, LMPs, and EBERs), seen in immunodeficiency-related lymphoproliferative diseases.
The EBV genome exhibits significant genetic heterogeneity, with variation hotspots in immune-regulatory genes like LMP1 and the EBNA2/3 family, as well as in key viral replication genes. These variations affect viral protein immunogenicity and oncogenic potential, posing challenges for precise immunotherapy target selection.
  1. MHC-I Tetramer Technology Boosts NPC Immunotherapy Development
CD8⁺ T cells, via TCR, specifically recognize MHC-antigen peptide complexes to eliminate virus-infected and tumor cells. In 1996, Altman's team first developed MHC-antigen peptide tetramer technology, enabling single-cell-level detection and analysis of antigen-specific T cells by flow cytometry. This technology, superior to traditional cytokine-secretion or cytotoxicity assays, allows simultaneous T cell quantification, phenotyping, and functional assessment, and is now a core tumor immunomonitoring tool.
For Chinese-population-prevalent HLA-A0201/A1101/A*2402 alleles, the research team has constructed a series of EBV-specific MHC-I tetramer reagents using EBV-oncoprotein epitope prediction algorithms. This platform efficiently analyzes antigen-specific T cell responses in EBV-related tumors like NPC, offering key technical support for EBV-targeted vaccine development, TCR-T cell therapy, and immunotherapy-efficacy monitoring.

相关产品推荐

病原/肿瘤 产品名称 抗原 序列 MHC 位置 货号
EBV HLA-A*0201/YLELLVWRL-PE Labelled Tetramer EBV.LMP1 YLELLVWRL HLA-A*0201 125-133 UA089001
EBV HLA-A*0201/YLQQNWTL-PE Labelled Tetramer EBV.LMP1 YLQQNWTL HLA-A*0201 159-167 UA089003
EBV H-2Db(b)/RAHY-NIVTF-PE Labelled Tetramer HPV16.E7 RAHYNIVTF H-2Db 49-57 UA089002
HPV H-2K(b)/EVYDFA-FRQL-PE Labelled Tetramer HPV16.E6 EVYDFARDL H-2Kb 48-57 UA089004
HPV HLA-A*0201/KLP-DLCTL-PE Labelled Tetramer HPV18.E6 KLPDCTL HLA-A*0201 13-21 UA089005
HPV HLA-A*0201/KLTNT-GLYQL-PE Labelled Tetramer HPV18.E6 KLTNTGLYNL HLA-A*0201 92-101 UA089006
HPV HLA-A*0201/TLODIVIHL-PE Labelled Tetramer HPV18.E7 TLODIVIHL HLA-A*0201 7~15 UA089007
HPV HLA-A*0201/QFLNTL-FV-PE Labelled Tetramer HPV18.E7 QFLNTLFSV HLA-A*0201 88-97 UA089008
HPV HLA-A*1101/GVNHQLPAR-PE Labelled Tetramer HPV18.E7 GVNHQLPAR HLA-A*1101 43-52 UA089009
Influenza A Virus H-2D(b)/ASNENMETM-PE Labelled Tetramer Flu.NP ASNENMETM H-2Db 366-374 UA089010
Influenza A Virus H-2K(d)/TYQR-TRALY-PE Labelled Tetramer Flu.NP TYQRTRALY H-2Kd 147-155 UA089011
Influenza A Virus H-2D(b)/ASNEN-MDTM-PE Labelled Tetramer Flu.NP ASNENMDTM H-2Db 366-374 UA089012
LCMV H-2D(b)/KAVYNFATM-PE Labelled Tetramer GP 33 KAVYNFATM H-2Db 33-41 UA089013
LCMV H-2D(b)/FQPGQGFVK-PE Labelled Tetramer LCMV NP FQPGQGFVK H-2Db 396-404 UA089014
Tumor-related HLA-A*1101/VVGADGVK-PE Labelled Tetramer KRAS VVGADGVK HLA-A*1101 7~16 UA089015
Tumor-related HLA-A*1101/VVGAGVGK-PE Labelled Tetramer KRAS VVGAGVGK HLA-A*1101 7~16 UA089016
Tumor-related HLA-A*0201/KLVVGAGV-PE Labelled Tetramer KRAS KLVVGAGV HLA-A*0201 5~14 UA089017
Tumor-related HLA-A*0201/SLLMWITQC-PE Labelled Tetramer NY-ESO1 SLLMWITQC HLA-A*0201 157-165 UA089018
Melanoma HLA-A*0201/LMWITQCFL-PE Labelled Tetramer NY-ESO2 LMWITQCFL HLA-A*0201 159-167 UA089019
Melanoma H-2Db(b)/MMFPNA-P1-PE Labelled Tetramer WT1 RMFPNAPL H-2Db 126-134 UA089020
Melanoma HLA-A*0201/CMTWV-PE Labelled Tetramer WT2 CMTWVNMDM HLA-A*0201 235-243 UA089021
Melanoma HLA-A*1101/KTCQRKSF-PE Labelled Tetramer WT3 KTCQRKSF HLA-A*1101 386-394 UA089022
Ovarian Cancer H-2K(b)/SINFEKL-PE Labelled Tetramer OVA SINFEKL H-2Kb 257-264 UA089023

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
公众号
公众号 more products
Product Information
The Last The Next
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.